Mc Adam, LLC Leap Therapeutics, Inc. Transaction History

Mc Adam, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 24, 2023	BUY	$0.29 - $0.72 $3,768 - $9,355	12,994 Added 39.64%	45,778 $15,000
Q4 2022 Jan 27, 2023	SELL	$0.42 - $9.18 $5,960 - $130,282	-14,192 Reduced 30.21%	32,784 $106,000
Q3 2022 Oct 24, 2022	SELL	$0.92 - $9.3 $4,140 - $41,850	-4,500 Reduced 8.74%	46,976 $41,000
Q2 2022 Jul 15, 2022	BUY	$0.96 - $1.91 $2,487 - $4,948	2,591 Added 5.3%	51,476 $59,000
Q1 2022 Apr 07, 2022	BUY	$1.6 - $3.35 $25,761 - $53,938	16,101 Added 49.11%	48,885 $86,000
Q4 2021 Jan 07, 2022	SELL	$2.08 - $3.65 $520 - $912	-250 Reduced 0.76%	32,784 $106,000
Q3 2021 Oct 05, 2021	SELL	$1.35 - $4.01 $4,004 - $11,893	-2,966 Reduced 8.24%	33,034 $132,000
Q2 2021 Aug 02, 2021	BUY	$1.48 - $1.92 $26,067 - $33,816	17,613 Added 95.79%	36,000 $51,000
Q1 2021 Apr 26, 2021	SELL	$1.82 - $3.01 $26,590 - $43,976	-14,610 Reduced 44.28%	18,387 $35,000
Q4 2020 Jan 12, 2021	BUY	$1.49 - $2.37 $49,165 - $78,202	32,997 New	32,997 $72,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Mc Adam, LLC, based on Form 13F filings with the SEC.

Stay updated on Mc Adam, LLC with notifications on news.